glp-1 drugs microdosing Why we launched Noom's Microdose GLP-1Rx Program GLP-1 Microdosing: Why Smaller Doses

Abstract Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality

Despite demonstrating robust glycemic efficacy, both agents were eventually discontinued due to distinct tolerability and safety concerns, diverging in severity and clinical implications

Vasodilatory Actions of Glucagon-like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans with Vascular Insulin Resistance

Global burden of 87 risk factors in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019

Impact of treatment with saxagliptin on glycaemic stability and beta-cell function in the SAVOR-TIMI 53 study

Attempts should be made to control preprandial blood glucose with basal/slow-acting insulins first, and then to control post-prandial blood glucose with rapid-acting insulin